Sylvain Perruche/LinkedIn
Apr 4, 2026, 08:36
Sylvain Perruche: Reactivating the Body Own Resolution Program in Inflammatory Disease
Sylvain Perruche, Founder and CEO of Med’Inn’Pharma, Co-Founder and Member of the Scientific Committee at Innovative Therapies Days, shared a post on LinkedIn:
“Inflammatory diseases have traditionally been treated by blocking the immune system.
Over the past decades, therapies have evolved:
- from broad immunosuppression
- to targeted cytokine inhibition
- to cell therapies
But the next frontier may be different.
Instead of suppressing inflammation, what if we could reactivate the body’s own resolution program?
At Med’Inn’Pharma, we are developing macrophage-derived secretome therapeutics designed to restore immune homeostasis and promote tissue repair.
A shift from blocking inflammation – resolving it.”

Stay updated with Hemostasis Today.
-
Nov 20, 2026, 00:33Overcoming Barriers to Diagnosis and Treatment for Women With Bleeding Disorders – EHC
-
Nov 20, 2026, 00:27Vera Stroikova: Key Takeaways on Electrophysiology and Stroke Prevention From the New Horizons 2026
-
Nov 20, 2026, 00:20Devi G. Nair Enrolls First US Patient in Smartphone Camera Atrial Fibrillation Detection Study
-
Nov 20, 2026, 00:14Saskia de Pee: Fortified Rice Cuts Anemia Risk by 57%
-
Nov 20, 2026, 00:02Andres Zuleta: Evaluating the RISE UP Trial Results on Mitapivat for Sickle Cell Disease
-
Nov 19, 2026, 23:57Greta Hametner: Preventing Maternal Cardiac Complications Through Preconception Iron and Thyroid Screening
-
Nov 19, 2026, 23:49Cyrus Shariat: Why Waiting for Lab Results Can Be Fatal in HIT
-
Nov 19, 2026, 22:24Erik Nelson: Low Iron Can Raise A1c without Changing Blood Sugar
-
Nov 19, 2026, 22:23Erwin Loh: Daily Iron Supplementation Reduces Iron-Deficiency Anaemia in Children and Adolescents